School of Biomedical Sciences, Faculty of Health, University of Plymouth, Plymouth, United Kingdom.
School of Dentistry, Faculty of Health, University of Plymouth, Plymouth, United Kingdom.
Br J Biomed Sci. 2023 Jun 16;80:11065. doi: 10.3389/bjbs.2023.11065. eCollection 2023.
Oral squamous cell carcinoma (OSCC) is a common malignant cancer in humans. An abundance of tumour associated macrophages (TAMs) create an immunosuppressive tumour microenvironment (TME). TAM markers (CD163 and CD68) are seen to serve as prognostic factors in OSCC. PD-L1 has seen to widely modulate the TME but its prognostic significance remains controversial. The aim of this meta-analysis is to evaluate the prognostic role of CD163, CD68 TAMs and PD-L1 in OSCC patients. Searches in PubMed, Scopus and Web of Science were performed; 12 studies were included in this meta-analysis. Quality assessment of included studies was performed according to REMARK guidelines. Risk of bias across studies was investigated according to the rate of heterogeneity. Meta-analysis was performed to investigate the association of all three biomarkers with overall survival (OS). High expression of CD163 TAMs were associated with poor overall survival (HR = 2.64; 95% Cl: [1.65, 4.23]; < 0.0001). Additionally, high stromal expression of CD163 TAMs correlated with poor overall survival (HR = 3.56; 95% Cl: [2.33, 5.44]; < 0.00001). Conversely, high CD68 and PD-L1 expression was not associated with overall survival (HR = 1.26; 95% Cl: [0.76, 2.07]; = 0.37) (HR = 0.64; 95% Cl: [0.35, 1.18]; = 0.15). In conclusion, our findings indicate CD163 can provide prognostic utility in OSCC. However, our data suggests CD68 TAMs were not associated with any prognostic relevance in OSCC patients, whereas PD-L1 expression may prove to be a differential prognostic marker dependent on tumour location and stage of progression.
口腔鳞状细胞癌 (OSCC) 是人类常见的恶性肿瘤。大量肿瘤相关巨噬细胞 (TAM) 会形成免疫抑制性肿瘤微环境 (TME)。TAM 标志物 (CD163 和 CD68) 被认为是 OSCC 的预后因素。PD-L1 已被广泛证明可以调节 TME,但它的预后意义仍存在争议。本荟萃分析旨在评估 CD163、CD68 TAMs 和 PD-L1 在 OSCC 患者中的预后作用。在 PubMed、Scopus 和 Web of Science 中进行了检索;共有 12 项研究纳入本荟萃分析。根据 REMARK 指南对纳入研究进行质量评估。根据异质性发生率调查了研究间的偏倚风险。进行荟萃分析以研究所有三种生物标志物与总生存期 (OS) 的相关性。CD163 TAMs 的高表达与总生存期不良相关 (HR = 2.64;95% Cl:[1.65, 4.23];<0.0001)。此外,CD163 TAMs 的基质高表达与总生存期不良相关 (HR = 3.56;95% Cl:[2.33, 5.44];<0.00001)。相反,高 CD68 和 PD-L1 表达与总生存期无关 (HR = 1.26;95% Cl:[0.76, 2.07];=0.37) (HR = 0.64;95% Cl:[0.35, 1.18];=0.15)。综上所述,我们的研究结果表明 CD163 可提供 OSCC 的预后效用。然而,我们的数据表明 CD68 TAMs 与 OSCC 患者的任何预后相关性无关,而 PD-L1 表达可能取决于肿瘤位置和进展阶段,成为一种不同的预后标志物。